Back to Search

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)

  • Protocol Number: 202009029
  • Principal Investigator: Bagegni, Nusayba
  • Cancer Types: Breast

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions